Replimune News Releases https://ir.replimune.com/ Replimune News Releases en Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab https://ir.replimune.com/news-releases/news-release-details/replimune-announces-initiation-phase-2-portion-its-ongoing-phase Trial in Progress Poster to be Presented Today at the 2019 American Society of Clinical Oncology Annual Meeting WOBURN, Mass. , June 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ Sat, 01 Jun 2019 09:00:00 -0400 Replimune News Releases 6936 Replimune to Present at Upcoming Investor Conferences https://ir.replimune.com/news-releases/news-release-details/replimune-present-upcoming-investor-conferences WOBURN, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team, will present and host investor meetings at the Thu, 30 May 2019 08:00:00 -0400 Replimune News Releases 6921 Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting https://ir.replimune.com/news-releases/news-release-details/replimune-announces-poster-presentation-2019-american-society Poster highlights progress in the ongoing Phase 1/2 clinical trial of RP1 alone & in combination with nivolumab WOBURN, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ Thu, 16 May 2019 07:00:00 -0400 Replimune News Releases 6906 Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019 https://ir.replimune.com/news-releases/news-release-details/replimune-announces-presentation-american-association-cancer WOBURN, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that pre-clinical data on its oncolytic immunotherapy platform will be presented at a Mon, 01 Apr 2019 07:00:00 -0400 Replimune News Releases 6836 Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update https://ir.replimune.com/news-releases/news-release-details/replimune-reports-financial-results-third-fiscal-quarter-ended RP1 : Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial  in the UK ; Part 1 Enrollment Opened for Combination with Nivolumab in Patients with Solid Tumors in the US RP1 : Opening of Part 2 in Defined Tumor Cohorts On Track for First Half 2019 RP1 :  Randomized Thu, 14 Feb 2019 08:00:00 -0500 Replimune News Releases 6791 Replimune to Present at Two Upcoming Investor Conferences https://ir.replimune.com/news-releases/news-release-details/replimune-present-two-upcoming-investor-conferences WOBURN, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will participate Thu, 07 Feb 2019 08:00:00 -0500 Replimune News Releases 6766 Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference https://ir.replimune.com/news-releases/news-release-details/replimune-highlights-company-progress-and-expected-2019 RP1 : U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1 : Randomized Controlled Phase 2 Clinical Trial Alone and in Combination with Cemiplimab On Track to Initiate H1 2019 RP2 : Phase 1 Clinical Trial Alone and in Combination with Thu, 03 Jan 2019 08:00:00 -0500 Replimune News Releases 6751 Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference https://ir.replimune.com/news-releases/news-release-details/replimune-present-37th-annual-jpmorgan-healthcare-conference WOBURN, Mass. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will present at Thu, 20 Dec 2018 08:00:00 -0500 Replimune News Releases 6741 Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference https://ir.replimune.com/news-releases/news-release-details/replimune-present-bmo-capital-markets-2018-prescriptions-success WOBURN, Mass. , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will present at Wed, 05 Dec 2018 08:00:00 -0500 Replimune News Releases 6726 Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update https://ir.replimune.com/news-releases/news-release-details/replimune-reports-financial-results-second-fiscal-quarter-ended U.S. Clinical Sites for Phase 1/2 Trial of RP1 in Patients with Solid Tumors on Track to Initiate by End of Year Additional Product Candidates RP2 and RP3 Continue to Advance Toward the Clinic WOBURN, Mass. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. Wed, 14 Nov 2018 08:00:00 -0500 Replimune News Releases 6711